The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of emavusertib (CA-4948) in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated, unresectable gastric and esophageal cancer.
 
Patrick Grierson
Employment - Walgreens (I)
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Ramon Jin
No Relationships to Disclose
 
Olivia Aranha
Honoraria - Johnson & Johnson/Janssen; OncLive/MJH Life Sciences
Consulting or Advisory Role - Seagen
Research Funding - Artios (Inst); AstraZeneca (Inst); Compass Therapeutics (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Moh'd Khushman
Stock and Other Ownership Interests - Cardiff Oncology; Caris Life Sciences; Moderna Therapeutics
Consulting or Advisory Role - Abbvie; bristol-myers squibb; Cardinal Health; Elevar Therapeutics; Exelixis; Guardant Health; Merus NV; TriSalus Life Sciences
Research Funding - Abbvie (Inst); BeiGene (Inst); FOGPharma (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Merus NV (Inst); Torl Biotherapeutics (Inst)
 
Kian-Huat Lim
Honoraria - CURIS
Patents, Royalties, Other Intellectual Property - Hold patent for targeting MK2 as a therapeutic strategy in pancreatic cancer.